The 21st Century War on Cancer

When US President Richard M. Nixon declared war on cancer in his 1971 state of the union address, his inspiration was the idea that millions of dollars thrown into the development of new and better chemotherapies would mean an end to the ancient scourge. It did not take long for even the most hawkish advocates of heavy investment in chemotherapeutic drug development to admit that victory was far in the future. John Cairns, a microbiologist now retired from the Harvard School of Public Health,

Written byPeg Brickley
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

When US President Richard M. Nixon declared war on cancer in his 1971 state of the union address, his inspiration was the idea that millions of dollars thrown into the development of new and better chemotherapies would mean an end to the ancient scourge. It did not take long for even the most hawkish advocates of heavy investment in chemotherapeutic drug development to admit that victory was far in the future.

John Cairns, a microbiologist now retired from the Harvard School of Public Health, was a leading early critic of the Nixon war on cancer, which he said put too much hope into treatment, and too little study into epidemiology. Still, some successes in treatment and early detection may have helped drive the breast cancer death rate down, he now thinks, but even doing the math, cancer by cancer, does not provide all the answers. "Stomach cancer has disappeared for ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies